Medication info
Empacombi Extended-Release Tablet 25/1000 mg (Empagliflozin, Metformin)

Empacombi Extended-Release Tablet 25/1000 mg (Empagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletEmpagliflozin Amorphous›25mg / 1 tablet
Manufacturer / importer
Aprogen Pharmaceuticals Co., Ltd.
Appearance
Pink oblong extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202500764 · Approved 2025.04.01 · Insurance code 645211070

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, this drug may be administered as 1 tablet once daily with a meal to patients receiving empagliflozin 25mg and metformin hydrochloride (extended-release) 1000mg. To reduce gastrointestinal adverse reactions caused by metformin, take this drug once daily with the evening meal. To maintain its extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. ⦁ When switching from concomitant therapy with empagliflozin and metformin to this drug, use the patient's existing doses of empagliflozin and metformin. When converting from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. ⦁ When this drug is coadministered with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of hypoglycemia. Because dose adjustment according to renal function is necessary, assessment of renal function is recommended before starting this drug and periodically thereafter. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this drug may be used with adjustment of the metformin hydrochloride dose as follows, if it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, do not initiate treatment with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, discontinue this drug immediately. In patients aged 75 years and older, consider renal function and the risk of volume depletion.

Ingredients

Manufacturer
Aprogen Pharmaceuticals Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Blood glucose disorder
  • type 2 diabetes
  • cardiovascular disease
View approved original text

This medication is used to help control blood glucose levels in adults with type 2 diabetes in conjunction with dietary and physical exercise therapies. It is particularly suitable for patients whose blood glucose is not adequately controlled, and some patients with cardiovascular diseases should refer to the physician's notes. This medication effectively improves blood glucose control by administering empagliflozin and metformin together.

How to take

Adult dose

For antidiabetic therapy, this drug may be administered as 1 tablet once daily with a meal to patients receiving empagliflozin 25mg and metformin hydrochloride (extended-release) 1000mg. To reduce gastrointestinal adverse reactions caused by metformin, take this drug once daily with the evening meal. To maintain its extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. ⦁ When switching from concomitant therapy with empagliflozin and metformin to this drug, use the patient's existing doses of empagliflozin and metformin. When converting from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. ⦁ When this drug is coadministered with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of hypoglycemia. Because dose adjustment according to renal function is necessary, assessment of renal function is recommended before starting this drug and periodically thereafter. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this drug may be used with adjustment of the metformin hydrochloride dose as follows, if it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, do not initiate treatment with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, discontinue this drug immediately. In patients aged 75 years and older, consider renal function and the risk of volume depletion.

Precautions

This medication is used for the treatment of type 2 diabetes, acting with two components to control blood glucose. While taking this medication, a rare side effect called lactic acidosis may occur, so if symptoms such as shortness of breath, muscle pain, and fatigue arise, immediate consultation with a physician is necessary. Also, when taken with insulin or sulfonylurea medications, there is a risk of hypoglycemia, so blood glucose levels should be carefully monitored. Patients with impaired kidney function or acute renal failure should not use this medication and should undergo regular kidney function tests. Avoid administration in cases of acute infections, dehydration, severe heart failure, and liver dysfunction, and temporary discontinuation is necessary when surgery is planned or contrast agent examinations are to be conducted. This medication may increase the risk of genital and urinary tract infections; hence, rapid treatment should be sought if infection symptoms occur. Vitamin B12 levels may decrease, so monitoring through blood testing is recommended when used long-term. Pregnant or breastfeeding women should not take this medication, particularly if there is a possibility of pregnancy. Elderly patients or those at risk of fluid loss should carefully monitor for dehydration or hypotension symptoms and be well aware of hypoglycemia symptoms. Do not crush, chew, or break the tablets but swallow them whole; it is normal for the tablet coating to be excreted in stool. If an overdose occurs, immediately visit a medical institution for appropriate treatment as there is a risk of lactic acidosis. It is advisable to avoid alcohol consumption during the use of this medication and to inform the physician of any other medications being taken due to potential interactions. No special effects have been reported when operating vehicles or machinery; however, caution is necessary due to possible hypoglycemia or dizziness. To use this medication safely, regular blood tests and strict adherence to the physician's instructions are required.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • vaginitis
  • balanitis
  • other genital infections
  • urinary tract infections
  • perineal necrosis
  • decreased and deficiency of vitamin B12
  • ketoacidosis
  • lactic acidosis
Show 79 more
  • reduced fluid volume
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • taste disturbance
  • pruritus
  • rash
  • urticaria
  • erythema nodosum
  • increased urination
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • ischemic colitis
  • colon bleeding
  • chronic gastritis
  • headache
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • angina pectoris
  • unstable angina
  • insomnia
  • dizziness
  • postural dizziness
  • palpitations
  • arteriosclerosis
  • deep vein thrombosis
  • diabetic foot
  • dermal cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • discoid eczema
  • heat rash
  • sebaceous gland hyperplasia
  • urinary stones
  • hematuria
  • overactive bladder
  • renal mass
  • urinary retention
  • urinary pain
  • urinary abnormalities
  • vulvar pruritus
  • genital pruritus
  • hyperglycemia
  • hyponatremia
  • dyslipidemia
  • weight loss
  • diabetic retinopathy
  • dry eyes
  • cough
  • dyspnea
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid mass

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is best to maintain a storage temperature between 1 to 30 degrees Celsius. This will help maintain the effectiveness and safety of the medication over time.

Appearance and packaging

Appearance

Pink oblong extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.